# Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers

> **NCT03023787** · PHASE1 · COMPLETED · sponsor: **Shanghai HEP Pharmaceutical Co., Ltd.** · enrollment: 35 (actual)

## Conditions studied

- Hepatitis B， Chronic

## Interventions

- **DRUG:** Hepalatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03023787
- **Lead sponsor:** Shanghai HEP Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03023787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03023787, "Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03023787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*